SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 26.86 |
| Enterprise Value ($M) | 26.51 |
| Book Value ($M) | -2.82 |
| Book Value / Share | -0.12 |
| Price / Book | -9.53 |
| NCAV ($M) | -3.02 |
| NCAV / Share | -0.13 |
| Price / NCAV | -8.90 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -3.65 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.21 |
| Current Ratio | 0.21 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 0.79 |
| Assets | 0.98 |
| Liabilities | 3.80 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Rimon Gold Assets Ltd | 9.99 | ||
| 13G/A | Gordon Ariel | 6.90 | 0.73 | |
| 13G/A | Ben-Noon Alon | 19.98 | 1.19 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 45,379 | 355,211 | 12.78 | |
| 21,552 | 193,363 | 11.15 | |
| 17,739 | 131,935 | 13.45 | |
| 27,176 | 270,754 | 10.04 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NERV – Minerva Neurosciences, Inc. | NKTR – Nektar Therapeutics |
| NLSP – NLS Pharmaceutics AG | NRXP – NRx Pharmaceuticals, Inc. |
| NVCT – Nuvectis Pharma, Inc. |
Financial data and stock pages provided by
Fintel.io